Compare Sana Biotechnology Inc (SANA) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Direxion Daily S&P 500 Bull 3X Shares trades at $270.05. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | SPXL | |
|---|---|---|
Market Cap | $873.84M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $5.92 | $288.04 |
52-Week Low | $2.68 | $170.20 |
Enterprise Value | $848.03M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
SPXL is trading at $264.57, down 0.44% with a bearish technical signal. The ETF faces resistance at the 50-day moving average while support levels cluster around $262-$254. Recent news highlights S&P 500 valuation concerns with Shiller CAPE ratios approaching historic highs, creating headwinds for leveraged index products.
The leveraged ETF's performance remains tied to S&P 500 momentum amid mixed earnings sentiment. Key risks include market concentration in tech stocks and potential AI bubble concerns, while institutional analysis suggests the broader market may still deliver double-digit gains through 2026 despite valuation pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
